在44例胺碘酮(Amiodarone)治疗室上性或室性心律失常病人中确认了不良反应的临床预报因素.其中发生不良反应的31人(70.5%).各系统的不良反应发生率为:心血管系统36.4%(16/44),中枢神经系统(CNS)27.3%(12/44),胃肠道20.5%(9/44),眼15.9%(7/44),甲状腺13.6%(6/44),肝脏6.8%(3/44),肺4.5%(2/44).发生不良反应病人的平均治疗时间(129±100周)较未发生不良反应者(31±80周)为长(P=0.006),用药时间长者尤其容易出现心血管、胃肠道或甲状腺方面的不良反应.胺碘酮与去乙酰胺碘酮平均血浆浓度在发生CNS不良反应者中较高(2.8±1.8比2.1±1.0μg/mL,P=0.04),其它不良反应则否.年龄小于60岁是与皮肤不良反应有关的重要危险因素,肝脏不良反应者平 The clinical predictors of adverse reactions were confirmed in 44 patients with supraventricular or ventricular arrhythmias treated with amiodarone, 31 of whom (31.5%) had adverse reactions. The incidence of adverse reactions in each system was 36.4% (16/44) in the cardiovascular system, 27.3% (12/44) in the CNS, 20.5% (9/44) in the gastrointestinal tract, 15.9% (7/44) in the eye, 13.6% / 44), liver 6.8% (3/44), and lung 4.5% (2/44). The mean duration of treatment (129 ± 100 weeks) with adverse reactions was longer than that without adverse events (31 ± 80 weeks) (P = 0.006), especially in patients with elder medication, cardiovascular, gastrointestinal or thyroid adverse reactions are more likely.The mean plasma concentrations of amiodarone and acetaminophen are higher in patients with CNS adverse reactions (2.8 ± 1.8 vs 2.1 ± 1.0μg / mL, P = 0.04), other adverse reactions were not.An age less than 60 years old is an important risk factor associated with adverse skin reactions, liver adverse reactions were flat